Diabetes drug helps reduce rate of strokes
Researchers for Takeda Pharmaceuticals says that a new analysis of a year-old study of Actos demonstrates that patients with type 2 diabetes and a history of one stroke reduce their chances of a second stroke by 47 percent by taking the drug. Volunteers who added Actos to standard therapy saw the rate of second strokes drop from 10.2 percent in a placebo group to 5.6 percent. Researchers added that there was no apparent difference in stroke rates among patients who had never had a prior stroke. Actos makes the cells of patients with type 2 diabetes more sensitive to insulin, allowing a better response to their own naturally produced insulin. The new data comes from existing data drawn from a large clinical study that was completed a year ago.
- read the report on Actos from TradeArabia
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
